Coronary Artery Disease: A Continuum, Not a Threshold I n this issue of Mayo Clinic Proceedings, Wang et al 1 have substantially advanced our understanding of the prevalence, clinical importance, and long-term prognosis of nonobstructive coronary artery disease (CAD). They performed a detailed metaanalysis, involving a final sample size exceeding 1 million patients, using data from published databases assessing CAD by invasive coronary angiography or coronary computed tomographic (CT) angiography. The core databases spanned a 15-year period, and the authors specifically selected patients with nonobstructive disease (defined as 50% stenosis) and further stratified the data as representing mild CAD (20% to 50% stenosis) or no CAD (0% or <20% stenosis). The median follow up was 27.6 months (range, 6 months to 10 years). The prevalence of nonobstructive disease in patients with stable angina was an amazing 67%, although it varied depending on sex, clinical setting, and risk profile. The thoroughness and details of the presentation and the accumulated sample size of the meta-analysis have not only confirmed but substantially expanded the literature documenting that CAD is indeed a continuum of atherosclerotic plaque severity. Further, CAD-associated prognosis is incremental in terms of the extent of the atherosclerotic process in any given individual and not just a threshold for "percent stenosis" as has been suggested for many years on the basis of invasive angiographic data.
Invasive coronary angiography, the acknowledged reference standard for defining coronary artery narrowing or stenosis, was available experimentally more than 60 years ago and has been available clinically for nearly 50 years. Why has it taken so long for the realization of the nonbenign prognosis of nonobstructive CAD? In the remainder of this editorial, I will attempt to answer this question and expand on the concepts addressed by Wang et al. 1 
Conceptualizing CAD as a Threshold
The moniker/acronym CAD is commonly employed in many if not most scientific articles addressing heart disease diagnosis and prognosis. Even routine application of the Framingham risk equations, generally alluding to the future development of symptomatic coronary atherosclerotic disease in asymptomatic patients, indicates the highest risk group as "coronary artery disease risk equivalence." But what is the definition of CAD?
A workable definition of CAD is that coronary atherosclerotic plaque disease has reached such a severity that (1) cardiac-related events (eg, sudden cardiac death, myocardial infarction, unstable angina) have been documented or (2) there is a situation in which exercise-or effort-induced angina pectoris due to ischemia can be provoked and documented/mimicked in the clinical laboratory. The traditional angiographic/perfusion/functional imaging definition of CAD has relied considerably on at least 1 of 2 scenarios: (1) documented focal coronary artery stenosis of 50% or more diameter or the presence of clear exercise/pharmacologically induced regional perfusion defects (nuclear medicine) or (2) inducible regional wall motion abnormalities (both nuclear medicine and 2-dimensional echocardiography). I can recall that for many years before and even after my initial cardiovascular diseases fellowship that any coronary lesion with less than 50% stenosis noted on direct coronary angiography was often called "normal." Patients were reassured that since there was no evidence for "obstructive" disease, they did not have CAD. Apparently only obstructive coronary lesions resulted in cardiac events.
What are the origins of such notions of the definition of CAD? The presence of CADassociated clinical events is clearly understood to mean CADdbut what about the issue of "percent coronary stenosis"? First, one needs to understand the concept of coronary flow and coronary flow reserve (CFR). The myocardium acts somewhat differently from most arterial vascular bedsdoxygen extraction is nearly maximal under normal resting circumstances, and the only way to improve oxygen delivery is to increase the flow rate (hyperemia). Katz and Linder 2 reported the relationship between CFR and ischemia in 1939. In experimental animal models, the process of measuring CFR is straightforwarddfirst observe/measure the flow at rest, then occlude a coronary artery temporarily (in practice, 20 seconds is sufficient), and then observe/measure the subsequent hyperemic flow. The maximum hyperemic response expressed as the number of times the flow rate increases above the resting rate is called the flow reserve. In experimental animals and in humans, the hyperemic response or CFR is generally 4 to 6 times the resting rate. Marcus et al 3 used an epicardial Doppler flowmeter in the operating room before aortic valve surgical procedures in a group of patients with clinical angina pectoris and severe left ventricular hypertrophy but "normal" coronary arteries on angiography. They reported decreased CFR as a likely mechanism for the clinical symptoms. The interpretation was that because of the severe left ventricular hypertrophy, resting coronary flow demand was much higher than normal and resulted in limitations for sufficiently augmenting coronary flow on demand.
In 1974, Gould and Lipscomb 4 reported the effects of coronary artery stenoses on CRF in dogs. An adaptation of their original data set is presented in the Figure, which notes that resting coronary flow (in dogs, which do not naturally have development of coronary atherosclerotic disease) decreased only after a discrete and single coronary artery epicardial stenosis exceeded 80% to 85%. It is also apparent from the Figure that the maximum CFR begins to decrease at 50% diameter stenosis. This extrapolation from an animal model originated the concept that a 50% stenosis is potentially "hemodynamically significant" in humans. Recall that the first coronary artery angioplastyda procedure aimed at reducing luminal narrowingdwas performed by Gruentzig in 1974 and largely cemented the concepts that (1) coronary artery stenosis contributed to CAD and (2) procedural relief of stenosis lessens coronary symptoms and improves outcomes. At this point, the world accepted 50% or more stenosis as the "significant" CAD threshold and never looked back! Coronary reserve flow is a useful concept, but the ability for the human coronary arteries, under nondiseased circumstances, to increase coronary blood flow 4-to 6-fold on demand does not exactly translate to what we, as clinicians, encounter in clinical practice on a daily basis. Nuclear medicine imaging techniques using injected blood flow tracers such as technetium 99m Tc sestamibi can estimate CFR no higher than 2.5-to 3.0-fold (see Figure) . Thus, potential "ischemia" (ie, the failure for specific regional CFR to increase the same as other myocardial regions during provocation) using nuclear flow markers identifies only a CFR below the value of 2.0-to 2.5-fold and would be "normal" at a 3-fold increase. Under maximum stress testing, in the absence of true myocardial ischemia, coronary flow increases only about 2.5-fold in humans. An "early positive" stress test result suggests that maximum CRF represents approximately 1.5-fold or less increase from resting flow.
Over the years, the concept of 50% or greater stenosis as potentially hemodynamically important has become the clinical standard for publications, although according to Gould and Lipscomb 4 and shown graphically on the Figure, a 50% stenosis corresponds to a flow reserve of less than 3.5-fold, which could still be "normal" on conventional stress testing. A CRF decrease to less than 3.0-fold actually corresponds to a 70% stenosis (Figure) , which has now become the de facto stenosis measurement supported by catheter-based fractional flow reserve data defining the appropriateness for potential benefit of coronary interventions of all but the left main coronary artery. 5 Fractional flow reserve is a pressure-derived determination of hyperemic capacity of the coronary artery in question and is closely related to the flow-derived CFR.
Conceptualizing CAD as a Continuum
Now that we have discussed the potential of clinical CAD to relate to some sort of fixed thresholddwhether it is a percent diameter stenosis of 50% to 70% or greater or the potential for clinically manifested ischemiadit is time to pose the opposite question. "What is not CAD?" The answer to that question requires more thought. One answer commonly voiced worldwide is that the amount of coronary atherosclerotic plaque disease present is nonobstructive or limited in extent such that cardiac-related events have not occurred and there is no clear evidence of previous heart damage or inducible/ efforterelated ischemia. Based on these concepts, many cardiologists have said something like this to patients: "Congratulations. Your stress test result was negative" or "your coronary arteriogram revealed no abnormalities" or "showed only luminal irregularities. In short, you do not have CAD!"
The concept of nonobstructive CAD, no matter what definition you use, is that it is more benign than obstructive disease. In fact, the original Coronary Artery Surgery Study suggested this concept. The Coronary Artery Surgery Study investigations noted that cardiac events were highest for those with triplevessel (obstructive) coronary disease, followed by double-vessel obstructive disease, followed by single-vessel obstructive disease, and events were lowest for those with no obstructive disease. 6 In other words, the greater the extent of coronary atherosclerotic plaque involvement the greater the risk for future coronary-related events, but even having no obstructive disease still garnered some risk.
When my colleagues and I advocated the use of coronary artery calcium scoring using noncontrast CT as a surrogate for defining the extent of coronary atherosclerotic plaque rather than percent stenosis, 7, 8 many practicing cardiologists thought that coronary artery calcification was "false-positive" because some individuals, mistakenly referred for cardiac catheterization, did not have any obstructive CAD.
As methods to define subclinical CAD progresseddespecially as noncontrast and contrast cardiac CT became more established in clinical practicedstudies looking at prognosis in those with nonobstructive disease were intensified. Bittencourt et al 9 used cardiac CT angiography to examine the prognostic value of nonobstructive and obstructive CAD as well as extent of atherosclerosis (defined by the number of diseased coronary segments). They noted that nonobstructive plaque in 3232 patients followed up for a median of 3.6 years was not benign and that in these patients, plaque extent was more powerful than maximum stenosis severity in predicting outcomes. Such observations reflect earlier research by Kern and Meier 10 using catheter-based intravascular ultrasound, who noted that "because the aggregate risk of rupture associated with many nonsignificant lesions.exceeds that of the fewer significant lesions, a myocardial infarction will more likely originate from a nonsignificant lesion." . Overlaid is the maximum or physiologic limit of coronary artery flow reserve using nuclear stress imaging as applied in humans. See text for details.
Maddox et al
11 conducted a retrospective cohort study of US military veterans undergoing elective coronary angiography between October 2007 and September 2012 (total of 37,674 patients). The primary outcome was 1-year hospitalization for nonfatal myocardial infarction, and the secondary outcome was all-cause mortality. The results clearly showed a gradient for the hazard ratio for myocardial infarction or a continuum of risk at the most advanced level of observed diseased1.0 for no apparent CAD, 2.0 for 1-vessel nonobstructive disease, 4.6 for 2-vessel nonobstructive CAD, 9.0 for 1-vessel obstructive CAD, 16.5 for 2-vessel obstructive disease, and 19.5 for left main coronary artery or 3-vessel obstructive disease.
Bettencourt et al 9 (using noninvasive contrast-enhanced cardiac CT) and Maddox et al 11 (using invasive coronary angiography) were consistent in the message that cardiac prognosis relates to the continuum of coronary atherosclerotic plaque involvement. However, the study by Wang et al 1 dcombining the use of both CT and angiography with the largest sample size and longest follow-up reported in all the prior literaturedhas provided the much needed clarification of the prognostic gradient for advancing coronary atherosclerotic plaque involvement and cementing that the dichotomous "obstructive CAD" vs "nonobstructive CAD" should be modified.
Conclusion
In summary, although the acronym CAD is too ingrained and commonplace to remove from the clinical vernacular, we will gain cognitive functionality if we replace its meaning from "coronary artery disease" to "coronary atherosclerotic disease." This latter term better reflects the continuum of the disease process currently accounting for 1 of every 4 deaths in the United States.
